A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-0805 following administration of single ascending doses of ABBV-0805, administered as intravenous (IV) infusions…Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with Parkinson’s disease
Objective: To investigate whether plasma phosphorylated α-synuclein (p-syn) were associated with cognitive function in Parkinson’s disease (PD). Background: Parkinson’s disease (PD) is the second most…The Prodromal PD study – multiple biomarkers for early diagnosis?
Objective: The study aims to deepen our understanding of the prodromal phase of Parkinson’s disease (PD) Background: At the time of PD diagnosis, nigrostriatal degeneration…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…Dissociable contribution of serum NfL and p-tau181 to cognitive impairment and mild cognitive impairment in Parkinson’s disease.
Objective: To analyze the contribution of serum NfL and p-tau181 levels to cognitive impairment and mild cognitive impairment (PD-MCI) in non-demented PD patients. Background: Autopsy…GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies
Objective: To investigate whether post-translational modifications of α-synuclein will give rise to species that differ between PD cases with N370S GBA mutation and WT-PD. Background:…Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics
Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson’s disease
Objective: To report the identification of a novel variant in the gene encoding alpha-synuclein (SNCA), segregating with Parkinson’s Disease (PD) in two families of Turkish…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 51
- Next Page »